866-997-4948(US-Canada Toll Free)

Canavan Disease - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 29 Pages

Canavan Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H2 2016, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape.

Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene which directs the production of the enzyme aspartoacylase (ASPA) allows the buildup of N-acetylaspartic acid (NAA) in the brain. The buildup of NAA causes damage to myelin. Symptoms include lack of motor development, feeding difficulties, abnormal muscle tone, and an abnormally large, poorly controlled head, paralysis, blindness, or hearing loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Canavan Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Canavan Disease.

Canavan Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Canavan Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Canavan Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Canavan Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Canavan Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Canavan Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Canavan Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Canavan Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Canavan Disease Overview 5
Therapeutics Development 6
Pipeline Products for Canavan Disease - Overview 6
Pipeline Products for Canavan Disease - Comparative Analysis 7
Canavan Disease - Therapeutics under Development by Companies 8
Canavan Disease - Therapeutics under Investigation by Universities/Institutes 9
Canavan Disease - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Canavan Disease - Products under Development by Companies 12
Canavan Disease - Products under Investigation by Universities/Institutes 13
Canavan Disease - Companies Involved in Therapeutics Development 14
Turing Pharmaceuticals AG 14
Canavan Disease - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 17
Assessment by Molecule Type 19
Drug Profiles 21
Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Gene therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Recombinant Enzyme to Replace Aspartoacylase for Canavan Disease - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
TUR-007 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Canavan Disease - Dormant Projects 26
Canavan Disease - Discontinued Products 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
Number of Products under Development for Canavan Disease, H2 2016 6
Number of Products under Development for Canavan Disease - Comparative Analysis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Number of Products under Investigation by Universities/Institutes, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Canavan Disease - Pipeline by Turing Pharmaceuticals AG, H2 2016 14
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Stage and Target, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Canavan Disease - Dormant Projects, H2 2016 26
Canavan Disease - Discontinued Products, H2 2016 27

List of Figures
Number of Products under Development for Canavan Disease, H2 2016 6
Number of Products under Development for Canavan Disease - Comparative Analysis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Stage and Targets, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Types, H2 2016 19

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *